Final Patent Interference Decision Favors Sarepta Therapeutics (SRPT) - Baird

September 21, 2016 6:46 AM EDT Send to a Friend
Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Sarepta Therapeutic (NASDAQ: SRPT) after PTAB issued a decision ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login